Investigational drug · Phase 2
S247240
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Fragile X Syndrome (FXS).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "S247240"
First trial start
2027
Jan 25, 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "S247240", any sponsor or status.
Conditions studied
As listed on its trial records.
- Fragile X Syndrome (FXS)
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "S247240" as an intervention, largest first.
- A Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of S247240 in Adult Male Participants With Fragile X SyndromePivotal-lookingNot yet recruiting
Institut de Recherches Internationales Servier (I.R.I.S.)Industry
NCT07930520 · 100 participants (planned) · Start Jan 25, 2027 · Primary completion Dec 28, 2028
Drug: S247240 Low dose; S247240 Middle dose and 1 more · For: Fragile X Syndrome (FXS)
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Fragile X Syndrome (FXS)
- SPG601CodabakalnerPhase 32 trials
Spinogenix · Fragile X Syndrome (FXS), Autism Spectrum Disorder (ASD), Fragile X Syndrome
- cannabidiol as a clear that can be applied to the skinZYN002, transdermal deliveryPhase 31 trial
Harmony Biosciences Management, Inc. · Fragile X Syndrome, Fragile X Syndrome (FXS)
- CTH120Phase 21 trial
Connecta Therapeutics, S.L. · Fragile X Syndrome (FXS), Fragile X Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.